Novo Nordisk Launches Wegovy Weight-Loss Pill in US, Intensifying Price Competition

Novo Nordisk has launched its Wegovy weight-loss pill in the US, sparking a new price war. The once-daily pill is the first GLP-1 tablet on the market and costs far less than injectable alternatives. Self-paying patients can access starter doses for $149 a month, with insured patients paying from $25. The company aims to regain market share lost to rivals such as Eli Lilly, whose injectable drugs dominate the sector. The pill is now available through major US pharmacies and telehealth providers, with wider rollout planned. Novo hopes the needle-free option will attract new patients and revive growth after a difficult year.